01—Abstract
Summary
Summary of the 10-K filed June 12, 2002. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation's 2002 10-K filing reveals a company focused on its three core segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions.
The Pharmaceutical Solutions segment is the dominant revenue driver, accounting for 93%a of total revenues, and demonstrated significant growth in the fiscal year ended March 31, 2002. Despite the overall revenue increase, the company faced substantial legal challenges stemming from past accounting improprieties related to the HBOC acquisition, with numerous securities litigation cases ongoing. Management highlighted efforts to manage expenses and improve operational efficiency across its segments.
02—Key points
Key Highlights
- Pharmaceutical Solutions segment continues to be the primary revenue generator, contributing 93% of total revenues in FY2002, with a significant 19% increase in overall company revenue to $50.0 billion.
- The company is navigating significant legal proceedings related to accounting improprieties from the HBOC acquisition, with numerous securities litigation cases and investigations ongoing.
- Acquisitions and strategic investments were made during the period, including the formation of Verispan, L.L.C. and the agreement to acquire A.L.I. Technologies Inc., indicating a continued focus on expanding healthcare information and medical imaging capabilities.
- The Information Solutions segment experienced revenue growth, driven by new contracts for its Horizon Clinicals™ offerings, and a backlog of $2.1 billion for maintenance fees, software, and outsourcing agreements.
- The company is undergoing restructuring, particularly in its Medical-Surgical segment, involving the closure and opening of distribution centers, aimed at improving operational efficiency.
- McKesson's financial position shows increasing revenues but is also marked by significant 'special charges' and 'restructuring activities' impacting reported net income, though pro forma results indicate underlying operational improvements.
- The company is subject to various litigation and claims, including antitrust matters and product liability, with management stating that, aside from the accounting litigation, other matters are not expected to have a material adverse effect on financial position.
03—Questions
Frequently Asked Questions
What are McKesson's main business segments and which is the largest contributor to revenue?
McKesson operates through three main segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The Pharmaceutical Solutions segment is the largest contributor, accounting for 93% of total revenues in fiscal year 2002.
What significant legal issues is McKesson facing?
McKesson is involved in extensive securities litigation stemming from accounting improprieties discovered after the HBOC acquisition in 1999. Numerous lawsuits have been filed, and investigations by the SEC and U.S. Attorney's Office were ongoing, though the SEC had terminated its investigation into the company itself without recommending enforcement action.
How did McKesson perform financially in the fiscal year ended March 31, 2002?
McKesson reported total revenues of $50.0 billion, a 19% increase from the prior year. Net income was $418.6 million, a significant improvement from a net loss of $48.3 million in the previous year. However, these reported results included substantial 'special charges' and 'restructuring activities' that impacted profitability; pro forma results, which exclude these items, showed continued operational growth.
What are the company's key strategic initiatives or recent developments?
Key initiatives include the formation of a joint venture, Verispan, with Quintiles Transnational Corporation, and an agreement to acquire A.L.I. Technologies Inc. These moves indicate a focus on expanding capabilities in healthcare information and medical imaging. The company is also undertaking restructuring efforts, particularly in its Medical-Surgical segment, to optimize its distribution network.
04—Continue